2.35Open2.35Pre Close0 Volume126 Open Interest9.00Strike Price0.00Turnover119.10%IV13.50%PremiumJan 17, 2025Expiry Date1.00Intrinsic Value100Multiplier22DDays to Expiry1.35Extrinsic Value100Contract SizeAmericanOptions Type0.6961Delta0.1183Gamma5.88Leverage Ratio-0.0239Theta0.0032Rho4.09Eff Leverage0.0087Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet